Skip to main content
. 2017 Jan 17;32(4):458–463. doi: 10.1007/s11606-016-3957-y

Table 3.

Demographic Associations with Marijuana Beliefs

Range (highest possible) Male, M (SD) (n = 113) Female, M (SD) (n = 109) p Age <24, M (SD) (n = 65) Age 25–29, M (SD) (n = 124) Age 30+, M (SD) (n = 47) p * Have NOT used MJ, M (SD) (n = 92) Have used MJ, M (SD) (n = 138) p Did NOT live in CO, M (SD) (n = 63) Lived in CO, M (SD) (n = 173) p
Acceptability of MMJ for  treatment of approved  conditions 8–40 (48) 33.5 (9.1) 32.7 (8.8) 0.542 32.7 (8.5) 33.2 (8.5) 33.1 (11.0) 0.934 28.8 (9.3) 35.7 (7.69) 0.000§ 32.0 (9.4) 35.8 (7.6) 0.007§
Believe MJ has medical  benefits 5-30 (30) 16.6 (5.7) 16.0 (5.3) 0.452 16.4 (5.6) 16.0 (5.2) 17.2 (6.1) 0.451 14.4 (4.9) 17.4 (5.6) 0.000§ 9.3 (3.5) 9.9 (3.4) 0.233
Believe MJ has medical  risks 5–18 (18) 12.9 (2.9) 13.1 (2.9) 0.628 12.5 (3.1) 13.3 (2.6) 13.0 (3.3) 0.190 13.8 (2.7) 12.6 (3.0) 0.001§ 8.4 (2.2) 7.9 (2.3) 0.084
Support legal reform 3–18 (18) 13.2 (4.1) 12.0 (4.1) 0.024 12.8 (4.5) 12.5 (3.9) 13.0 (4.2) 0.763 10.8 (4.1) 13.9 (3.7) 0.000§ 12.5 (4.2) 13.4 (4.0) 0.125
Support MMJ training  & research 4–24 (24) 20.1 (2.9) 20.7 (3.0) 0.082 20.3 (3.3) 20.4 (3.0) 19.7 (4.0) 0.470 19.6 (3.4) 20.7 (3.1) 0.016 20.1 (3.4) 20.6 (2.8) 0.275
Support adverse  consequences for  physicians who  recommend MMJ 2–12 (12) 4.1 (2.2) 4.2 (1.9) 0.954 4.0 (1.8) 4.3 (2.1) 3.9 (2.3) 0.371 4.9 (2.3) 3.7 (1.7) 0.000§ 4.4 (2.1) 3.6 (1.7) 0.009

*One-way ANOVA for between-group differences; no contrasts met Bonferroni-adjusted p

Respondents who reported having never used marijuana in their lifetime

Respondents who reported having used marijuana at any point in their lifetime

§Independent-samples t test significant at Bonferroni-adjusted p < 0.008